Evidence map›Paper›PMID 24781193›Full record

ArticleImmunologic research2014

Depletion of inflammatory dendritic cells with anti-CD209 conjugated to saporin toxin.

Michael N Alonso, Josh G Gregorio, Matthew G Davidson, Joseph C Gonzalez, Edgar G Engleman

Open access · greenAbstract read
In one paragraph

Article in Immunologic research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. A Critical Role of DC-SIGNImmunoTargets and therapy · 2025
    Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Michael N AlonsoDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Josh G Gregorio
Matthew G Davidson
Joseph C Gonzalez
Edgar G Engleman
Stanford University · US

Funding

TLI/ATG CONDTIONING: KIDNEY/BLOOD STEM CELL TRANSPLANTSP01HL075462 · NHLBI · STANFORD UNIVERSITY · PI ENGLEMAN, EDGAR G. · 2004 to 2020
$27.9M
Lupus Glomenulonephritis and NK T cellsR01DK082537 · NIDDK · STANFORD UNIVERSITY · PI STROBER, SAMUEL · 2009 to 2013
$2.3M
Defining Adaptive Immune Mechanisms of Insulin ResistanceR01DK096038 · NIDDK · STANFORD UNIVERSITY · PI ENGLEMAN, EDGAR G. · 2012 to 2015
$1.5M
Characterization of Human Regulatory T cell-induced Dendritic CellsF31CA142272 · NCI · STANFORD UNIVERSITY · PI ALONSO, MICHAEL · 2009 to 2010
$83k
NCI NIH HHS F31 CA142272NHLBI NIH HHS P01 HL075462NIDDK NIH HHS R01 DK082537NIDDK NIH HHS R01 DK096038
6 · The paper itself

Abstract

Monocytes rapidly infiltrate inflamed tissues and differentiate into CD209(+) inflammatory dendritic cells (DCs) that promote robust immunity or, if unregulated, inflammatory disease. Previous studies in experimental animal models indicate that inflammatory DC depletion through systemic elimination of their monocyte precursors with clodronate-loaded liposomes ameliorates the development of psoriasis and other diseases. However, translation of systemic monocyte depletion strategies is difficult due to the importance of monocytes during homeostasis and infection clearance. Here, we describe a strategy that avoids the monocyte intermediates to deplete inflammatory DCs through antibody-loaded toxin. Mice with an abundance of inflammatory DCs as a consequence of lipopolysaccharide exposure were treated with anti-CD209 antibody conjugated to saporin, a potent ribosome inactivator. The results demonstrate depletion of CD209(+) DCs. This strategy could prove useful for the targeted reduction of inflammatory DCs in disease.

Indexed as

Leukocyte Reduction ProceduresAnimalsAntibodies, MonoclonalCell Adhesion MoleculesDC-Specific ICAM-3 Grabbing NonintegrinDendritic CellsDisease Models, AnimalFlow CytometryImmunotoxinsInflammationLectins, C-TypeMiceReceptors, Cell SurfaceRibosome Inactivating Proteins, Type 1SaporinsAntibodies, MonoclonalCell Adhesion MoleculesDC-Specific ICAM-3 Grabbing NonintegrinImmunotoxinsLectins, C-TypeReceptors, Cell SurfaceRibosome Inactivating Proteins, Type 1Saporins

Identifiers

PMID24781193
PMCPMC4160227
OpenAlexW2127411681

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.